DOCSLIB.ORG

Workshop 2: Practical Approaches

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Workshop 2: Practical Approaches Examining the Impact of Real-World Evidence on Medical Product Development: A Workshop Series Workshop 2: Practical Approaches Workshop Briefing Materials Table of Contents 1. Workshop Information 2. Real-World Evidence Workshop Series Background Document 3. Workshop Agenda 4. Workshop Series Planning Committee Member Biographies 5. Workshop Speaker and Discussant Biographies 6. Literature Informing the Use Cases Being Discussed at the Workshop a. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation (Patel et al. for the ROCKET-AF Investigators, 2011) b. Prospective Surveillance Pilot of Rivaroxaban Safety Within the US Food and Drug Administration Sentinel System (Chrischilles et al., 2017) c. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study (Go et al., 2017) d. Lithium for Suicidal Behavior in Mood Disorders (Li+) (ClinicalTrials.gov record) e. Can Lithium Help Stem Suicide Rate? VA Study Aims to Find Out (VA Research Currents article) f. Use of Health Care Databases to Support Supplemental Indications of Approved Medications (Fralick et al., 2018) g. Comparison of Observational Data and the ONTARGET Results for Telmisartan Treatment of Hypertension: Bull’s-Eye or Painting the Target Around the Arrow? (Califf, 2018) Workshop Information Dates: March 6-7, 2018 Time: Day 1: 8:30am – 5:00pm Day 2: 8:30am – 12:30pm Location: National Academy of Sciences Building Room 120 2101 Constitution Ave NW Washington, DC 20418 Examining the Impact of Real-World Evidence on Medical Product Development: A Three-Part Workshop Series Washington, D.C. Background and Objectives Workshop Topics and Flow Workshop One (September 19-20, 2017) focused on Randomized, controlled clinical trials (RCTs) have how to align incentives to support collection and use traditionally served as the gold standard for evidence of real-world evidence in health product review, generation in support of medical product development and payment, and delivery. Incentives need to address approval. However, it is increasingly recognized that barriers impeding the uptake of real-world evidence, RCTs have inherent limitations, particularly with regard to including barriers to transparency. generalizability, and time and monetary investment. Data Workshop Two (March 6-7, 2018) will be a “town- from sources supplemental to RCTs, such as safety hall” style meeting to illuminate what types of data are surveillance, observational studies, registries, claims, or appropriate for what specific purposes and suggest patient-centered outcomes research, would be valuable to approaches for data collection and evidence use by support biomedical research, including medical product developing and working through example use cases. development and evaluation. Workshop Three (July 17-18, 2018) will examine and suggest approaches for operationalizing the This three-part workshop series will provide a format for collection and use of real-world evidence. examining the practicalities of collection of data from such real-world sources and deriving real-world evidence for the evaluation of medical products, including drugs, Planning Committee biologics, and devices. Each 1.5 day workshop will include presentations and perspectives from thought and Mark McClellan (Co-Chair), Duke-Margolis Center for knowledge leaders representing a range of disciplines, Health Policy including but not limited to federal regulatory and funding Gregory Simon (Co-Chair), Kaiser Permanente agencies, clinical and academic medicine and research, Washington Health Research Institute medical professional organizations, the regulated Jeff Allen, Friends of Cancer Research biopharmaceutical industry, patients and patient-focused Andrew Bindman, UCSF and disease-advocacy organizations, payers, consumer Adam Haim, NIMH, NIH organizations, health systems, and other interested Michael Horberg, Kaiser Permanente Mid-Atlantic stakeholders that represent the myriad views of those Medical Group involved in drug, biologic, and device discovery, Petra Kaufmann, NCATS, NIH development, translation, and regulation. The workshop Richard Kuntz, Medtronic, Inc. audiences are expected to be similarly diverse, and they Elliott Levy, Amgen Inc. will have opportunities to engage in discussion during the David Madigan, Columbia University workshops. The series will employ case studies to Deven McGraw, Ciitizen illustrate the current state and to illuminate potential ways Richard Platt, Harvard Medical School forward; staff or invited experts will prepare background Patrick Vallance, GlaxoSmithKline papers describing the characteristics of, and gaps in, Joanne Waldstreicher, Johnson&Johnson current data generation efforts. Thought leaders will be Marcus Wilson, HealthCore, Inc invited to react to and build on the papers. The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and the world. Our work helps shape sound policies, inform public opinion, and advance the pursuit of science, engineering, and medicine. For more information about these workshops, contact Amanda Wagner Gee ([email protected]). Examining the Impact of Real-World Evidence on Medical Product Development: A Three-Part Workshop Series Workshop Two: Practical Approaches March 6–7, 2018 National Academy of Sciences Building, Room 120 2101 Constitution Ave. NW, Washington, DC 20418 The National Academies of Sciences, Engineering, and Medicine (National Academies) is convening a three-part workshop series examining how real-world evidence development and uptake can enhance medical product development and evaluation. The workshops will advance discussions and common knowledge about complex issues relating to the generation and utilization of real-world evidence, including fostering development and implementation of the science and technology of real-world evidence generation and utilization. Workshop One (September 19-20, 2017) focused on how to align incentives to support collection and use of real-world evidence in health product review, payment, and delivery. Incentives need to address barriers impeding the uptake of real-world evidence, including barriers to transparency. Workshop Two (March 6-7, 2018) will illuminate what types of data are appropriate for what specific purposes and suggest practical approaches for data collection and evidence use by developing and working through example use cases. Workshop Three (July 17-18, 2018) will examine and suggest approaches for operationalizing the collection and use of real-world evidence. DAY 1: March 6, 2018 8:30 a.m. Breakfast Available Outside the Room 120 8:40 a.m. Welcome and Opening Remarks GREG SIMON, Workshop Series Co-Chair Investigator Kaiser Permanente Washington Health Research Institute SESSION I: WHEN CAN WE RELY ON REAL-WORLD DATA? Session discussion questions: When can we have confidence in EHR data from real-world practice to accurately assess study eligibility, key prognostic factors, and study outcomes? When can we have confidence in data generated outside of clinical settings (e.g., mobile phones, connected glucometers, connected blood pressure monitors)? When does adjudication or other post-processing of real-world data add value? Moderator: Greg Daniel, Duke-Margolis Center for Health Policy Session Discussants JESSE BERLIN Vice President and Global Head, Epidemiology Johnson & Johnson ANDY BINDMAN Professor of Medicine University of California San Francisco ADRIAN HERNANDEZ Vice Dean for Clinical Research Duke University School of Medicine 9:00 a.m. Introduction and background to inform the discussion: Novel oral anticoagulants in comparison with warfarin 9:20 a.m. Open discussion with audience What questions can characterize the utility of any real-world data source and signal reliability before a study is performed (examples below)? o When is accuracy good enough to reasonably and consistently identify the right population? o When is accuracy good enough to reasonably and consistently assess the exposure or intervention? o When is accuracy good enough to reasonably and consistently assess the right outcome? o Are there any big safety issues that would be missed? o Are there concerns about data collection or entry, particularly in relation to creating systemic bias? o When is expert adjudication necessary to confirm that the recorded data is reliable and/or reasonably complete? What information is needed to answer such questions? 10:40 a.m. BREAK (Workgroup participants gather to synthesize audience feedback) 11:00 a.m. Workgroup presents synthesis of audience feedback SESSION II: WHEN CAN WE RELY ON REAL-WORLD TREATMENT? Session discussion questions: When conducting research in a real-world setting, are there situations that would require special guidance, knowledge, or experience in order for clinicians to adequately monitor participant safety and respond appropriately to adverse events? When does variation between comparison groups (socioeconomic, demographic, etc.); in treatment fidelity; in provider behavior and preferences; or in adherence yield a valid signal about real-world effectiveness, and when is it just noise? Moderator: Khaled Sarsour, Genetech│A Member of the Roche Group Session Discussants MICHAEL HORBERG Executive Director, Research, Community Benefit, and Medicaid Strategy Executive Director, Mid-Atlantic Permanente Research Institute Kaiser Permanente Mid-Atlantic Permanente
Load more

Recommended publications
  • Jerry Avorn, MD Is Professor of Medicine at Harvard Medical
    Promoting Biomedical Innovation and Economic Value: New Models for Reimbursement and Evidence Development Participant Biographies Jerry Avorn, MD is professor of medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women's Hospital. An internist, geriatrician, and drug epidemiologist, he studies the intended and adverse effects of prescription drugs, physician prescribing practices, and medication policy. The division he founded and leads comprises physicians, epidemiologists, health policy analysts, statisticians, and computer scientists who work together to analyze the utilization and outcomes of prescription drugs in numerous settings. Dr. Avorn pioneered the “academic detailing” approach to continuing medical education, in which non-commercial, evidence-based information about drugs is provided to doctors through educational outreach programs run by public-sector sponsors. Such programs are now in use in the United States, Canada, Australia, and Europe. Dr. Avorn completed his undergraduate training at Columbia University in 1969, received the MD from Harvard Medical School in 1974, and completed a residency in internal medicine at the Beth Israel Hospital in Boston. He is a member of the Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines and is the author or co-author of over 275 papers in the medical literature on medication use and its outcomes, and of the book, Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs, now in its 11th printing. Robert Epstein, MD is Medco’s president of advanced clinical science and research, and chief clinical research and development officer. Dr. Epstein is responsible for all of Medco’s clinical research initiatives, including the Medco Research Institute™ and the United BioSource Research Divisions.
    [Show full text]
  • Variations in Pill Appearance of Antiepileptic Drugs and the Risk of Nonadherence
    ORIGINAL INVESTIGATION ONLINE FIRST Variations in Pill Appearance of Antiepileptic Drugs and the Risk of Nonadherence Aaron S. Kesselheim, MD, JD, MPH; Alexander S. Misono, MD, MBA; William H. Shrank, MD, MSHS; Jeremy A. Greene, MD, PhD; Michael Doherty; Jerry Avorn, MD; Niteesh K. Choudhry, MD, PhD Background: Generic prescription drugs are bioequiva- Results: The AEDs dispensed had 37 colors and 4 shapes. lent to brand-name versions but may not have consis- A total of 11 472 patients with nonpersistence were linked tent color or shape, which can cause confusion and lead to 50 050 controls. Color discordance preceded 136 cases to interruptions in medication use. We sought to deter- (1.20%) but only 480 controls (0.97%) (adjusted odds mine whether switching among different-appearing an- ratio [OR], 1.27 [95% CI, 1.04-1.55]). Shape discor- tiepileptic drugs (AEDs) is associated with increased rates dance preceded 18 cases (0.16%) and 54 controls (0.11%) of medication nonpersistence, which can have serious (OR, 1.47 [95% CI, 0.85-2.54]). Within the seizure dis- medical, financial, and social consequences. order diagnosis subgroup, the risk of nonpersistence af- ter changes in pill color was also significantly elevated Methods: We designed a nested case-control study of com- (OR, 1.53 [95%, CI 1.07-2.18]). mercially insured patients in the United States who initi- ated an AED. Cases were patients who became nonpersis- Conclusions: Changes in pill color significantly tent, defined as failure to fill a prescription within 5 days of the elapsed days supplied.
    [Show full text]
  • Aaron Seth Kesselheim Curriculum Vitae
    Harvard Medical School Curriculum Vitae Date Prepared: April 28, 2020 Name: Aaron Seth Kesselheim, M.D., J.D., M.P.H. Office Address: Division of Pharmacoepidemiology and Pharmacoeconomics Department of Medicine, Brigham and Women’s Hospital 1620 Tremont Street, Suite 3030 Boston, MA 02120 Home Address: 25 Hillcroft Rd Jamaica Plain, MA 02130 Work Phone: (617) 278-0930 Work E-mail: [email protected] Work Website: http://www.drugepi.org/faculty-staff-trainees/faculty/aaron-kesselheim/ Work Fax: (617) 232-8602 Place of Birth: Cherry Hill, NJ Education 1996 A.B. (summa cum History and Science Harvard University, laude) Cambridge, MA 2002 M.D. Medicine University of Pennsylvania School of Medicine, Philadelphia, PA 2002 J.D. (magna cum Law University of Pennsylvania laude) Law School, Philadelphia, PA 2007 M.P.H. Clinical Effectiveness Harvard School of Public Health (HSPH), Boston, MA Postdoctoral Training 6/02-6/03 Intern Internal Medicine Brigham and Women’s Hospital (BWH), Boston, MA 7/03-6/05 Resident Internal Medicine BWH 7/05-6/07 Fellow General Medicine and Health Care BWH / Harvard Medical Policy Research School (HMS) / HSPH, Boston, MA Faculty Academic Appointments 7/07-6/10 Instructor Medicine HMS 7/08- Research Associate Health Policy and Management HSPH 7/10-6/14 Assistant Professor Medicine HMS 7/14-4/19 Associate Professor Medicine HMS 5/19- Professor Medicine HMS 7/14-7/15 Visiting Associate Law Yale Law School Professor of Law 7/16-7/19 Irving S. Ribicoff Law Yale Law School Visiting Associate 1 Professor of Law 7/19-7/20 Sidley Austin-Robert Law Yale Law School D.
    [Show full text]
  • Implications for Patients and Health Policy Speaker Biographies
    What Evidence is Essential for New Medical Products? Implications for Patients and Health Policy June 13, 2014 AAAS Headquarters Washington, DC Speaker Biographies Jerry Avorn, M.D. Harvard Medical School Jerry Avorn is Professor of Medicine at Harvard Medical School and Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women's Hospital. An internist and drug epidemiologist, he studies the intended and adverse effects of prescription drugs, physician prescribing practices, and medication policy. The division he founded and leads comprises physicians, epidemiologists, health policy analysts, statisticians, and computer scientists who work together to analyze patterns of utilization and outcomes of prescription drugs in numerous settings. Dr. Avorn pioneered the “academic detailing” approach to continuing medical education, in which non-commercial, evidence-based information about drugs is provided to doctors through educational outreach programs run by public-sector sponsors. Such programs are now in use in the U.S., Canada, Australia, and Europe. Dr. Avorn did his undergraduate work at Columbia University in 1969, received the M.D. from Harvard Medical School in 1974, and completed a residency in internal medicine at the Beth Israel Hospital in Boston. He has served as a member of the Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines and is the author or co-author of over 400 papers in the medical literature on medication use and its outcomes, and of the book, Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs, now in its 11th printing. Robert Ball, M.D., M.P.H, Sc.M.
    [Show full text]
  • Susan Dudek, RD, CDN, BS
    Contributors Ryan Lloyd Albritton, MD Robert S. Langer, ScD Resident Physician Institute Professor Diagnostic Radiology Resident Department of Chemical Engineering Department of Radiology Massachusetts Institute of Technology UCSF Medical Center Cambridge, MA University of California, San Francisco San Francisco, CA Stephen C. Lazarus, MD Professor of Medicine Seth L. Alper, MD, PhD Department of Pulmonary & Critical Care Medicine Professor of Medicine, Harvard Medical School University of California, San Francisco Associate Physician, Department of Medicine San Francisco, CA Beth Israel Deaconess Medical Center Boston, MA Benjamin Leader, MD, PhD Senior Resident Physician April W. Armstrong, MD Department of Emergency Medicine Clinical Fellow Brown University Medical School Harvard Combined Dermatology Program, Harvard Medical Rhode Island Hospital School Providence, RI Department of Dermatology, Massachusetts General Hospital David C. Lewis, MD Boston, MA Donald G. Millar Distinguished Professor of Alcohol and Addiction Studies Ehrin J. Armstrong, MD, MSc Community Health and Medicine Clinical Fellow Center for Alcohol & Addiction Studies Department of Medicine Brown University Massachusetts General Hospital Providence, RI Boston, MA Allen Shuyuan Liu, MD Sarah R. Armstrong, MS, DABT Surgical Resident Senior Scientist Department of Surgery Cambridge Environmental Inc. Brigham and Women’s Hospital Cambridge, MA Boston, MA Ramy A. Arnaout, DPhil, MD Eng H. Lo, PhD Clinical Fellow in Pathology Professor, Radiology and Neurology Department
    [Show full text]
  • Download The
    Winter 2020–21 Columbia College Today THE GURUOF GOTHAM Mike Wallace ’64 is the “radical historian” behind the Pulitzer Prize-winning chronicles of New York City Columbia College’s distinctive academic experience is best achieved with a student body that is diverse in every way. Thanks to Columbia’s need-based, no-loan financial aid commitment, we can ensure that classes comprise students of all backgrounds, experiences and perspectives. In fact, more than 50 percent of Columbia College students receive financial assistance. Thousands of alumni, parents and friends have already contributed to the Core to Commencement campaign, helping to fulfill the College’s promise to fully meet each student’s demonstrated financial need, whether now or in the generations to come. Learn more and join the effort: college.columbia.edu/campaign. Contents Columbia College CCT Today VOLUME 48 NUMBER 2 WINTER 2020–21 EDITOR-IN-CHIEF Alexis Boncy SOA’11 EXECUTIVE EDITOR Lisa Palladino 14 20 30 DEPUTY EDITOR Jill C. Shomer ASSOCIATE EDITOR Anne-Ryan Sirju JRN’09 features FORUM EDITOR Rose Kernochan BC’82 14 CONTRIBUTING EDITORS James C. Katz ’72 The Guru of Gotham Alex Sachare ’71 Thomas Vinciguerra ’85 Mike Wallace ’64 is the “radical historian” behind the ART DIRECTOR Pulitzer Prize-winning chronicles of New York City. Eson Chan By Scott Meslow Published three times a year by Columbia College 20 for alumni, students, faculty, parents and friends. Star Search CHIEF COMMUNICATIONS AND MARKETING OFFICER Astrophysicist Rebecca Oppenheimer ’94 studies Bernice Tsai ’96 some of the oddest objects in the universe. ADDRESS By Matthew Hutson Columbia College Today Columbia Alumni Center 622 W.
    [Show full text]